RU
Pulmonology
Respiraphen® Air
Registration certificate:
LP-001943-RG-RU
INN:
Ipratropium Bromide + Fenoterol
Release form:
Metered Dose Inhaler (MDI)
Therapeutic Area:
Pulmonology
Pharmacotherapeutic Group:
Adrenergic agents for inhalation, Adrenergic agents in combination with anticholinergic agents, including triple combinations with corticosteroids.
Conditions for dispensing:
On prescription
Packaging:

Indications for Use:

Prevention and symptomatic treatment of obstructive airway diseases with reversible airway obstruction such as bronchial asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis with or without emphysema.

Included in the List of Essential Medicines.

Using Respiraphen® Air
 
Quality control
at all stages of production